OCUL
Ocular Therapeutix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.64
+0.00%Aug 3, 2026, 13:10 UTC
Ocular Therapeutix reported a second-quarter net loss of $0.35 per share, beating the Zacks Consensus Estimate of a $0.40 loss and improving from a $0.39 loss a year earlier.
Source:Jun 22, 2026, 20:05 UTC
Ocular Therapeutix granted inducement equity awards to new SVP Kelley Allison as a material inducement for her employment acceptance.
Jun 17, 2026, 13:45 UTC
Ocular Therapeutix announced that the FDA is aligned on its plan to submit a new drug application for Axpaxli injection for wet age-related macular degeneration.
Jun 12, 2026, 00:00 UTC
Ocular Therapeutix, Inc. appointed Jason S. Robins as Chief Financial Officer effective June 10, 2026.